Mirtazapine as a pre-shipping inhibitor of bovine respiratory disease

Patent metadata

Field	Value
Publication number	US-2021069206-A1
Application number	US-202016947607-A
Country	US
Kind code	A1
Filing date	Aug 10, 2020
Priority date	Sep 6, 2019
Publication date	Mar 11, 2021
Grant date	—

Abstract

Methods for preventing feedlot bovine respiratory diseases employing mirtazapine as pre-shipment treatments are disclosed. Compositions are further disclosed. Beneficially, the methods and compositions provide safe and cost-effective management of a costly disease.

First claim

What is claimed is:

1 . A method of preventing bovine respiratory disease (BRD) in a feedlot comprising:
administering to a population of cattle in need of BRD prevention a therapeutically effective amount of mirtazapine or one of its pharmaceutically acceptable derivatives; wherein the mirtazapine is administered to the cattle before they are shipped and at a frequency and for a duration of time effective to reduce the incidence of BRD by at least 50%.

2 . The method of claim 1 , wherein the therapeutic agent is orally-administered.

3 . The method of claim 2 , wherein the therapeutic agent is provided directly to the mouth of the animal or into the feed source for the animal and the dosage form is tablets, powder, capsules, solutions (aqueous or non-aqueous), suspensions, syrups, or emulsions.

4 . The method of claim 1 , wherein the therapeutic agent is administered by injection.

5 . The method of claim 4 , wherein the injection is in the form of a thixotropic liquid.

6 . The method of claim 4 , wherein the injection provides an implanted depot to provide modified release of the mirtazapine.

7 . The method of claim 1 , wherein the therapeutic agent is dosed at an amount between about 0.1 mg/kg to about 10 mg/kg.

8 . The method of claim 7 , wherein the therapeutic agent is dosed at an amount between about 1 mg/kg to about 5 mg/kg.

9 . The method of claim 1 , wherein the therapeutic agent is dosed at an amount between about 10 mg/day to about 100 mg/day.

10 . The method of claim 1 , wherein the therapeutic agent is dosed once per day and administered daily for up to 7 days or up to 14 days.

11 . The method of claim 1 , wherein the therapeutic agent is dosed by at least one injection either daily or in a single delayed or sustained release injection to provide controlled release of the therapeutic agent.

12 . The method of claim 1 , wherein the incidence of BRD is reduced by at least about 50% in the population of cattle.

13 . The method of claim 1 , wherein the prevention of BRD results in at least a 50% reduction in antibiotic usage within a facility housing the cattle.

14 . The method of claim 13 , wherein the prevention of BRD results in at least a 75% reduction in antibiotic usage within a facility housing the cattle.

15 . The method of claim 13 , wherein the incidence of antibiotic resistance is reduced among the population of cattle.

16 . The method of claim 1 , wherein the onset of BRD in the cattle is delayed and the mortality is decreased.

17 . The method of claim 16 , wherein the cattle having delayed onset of BRD have at least a 50% reduction in antibiotic retreatments.

18 . The method of claim 1 , wherein the rectal temperature of the cattle is less than the rectal temperature of a cattle not treated with the therapeutic agent.

19 . The method of claim 1 , wherein the therapeutic agent is absent from muscle tissues at three to six weeks post-withdrawal of the drug.

Assignees

• Univ Iowa State Res Found Inc

Inventors

• Carlson Steven Alan
• Day Tim

Classifications

• A23K50/10

  for ruminants · CPC title

• A23K20/132

  containing only one nitrogen as hetero atom · CPC title

• A23K20/111

  Aromatic compounds · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K9/0024

  Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L) · CPC title